Eli Lilly slashes insulin prices, bowing to Biden's pressure
Investing.com | Author Geoffrey Smith
Published Mar 01, 2023 08:17AM ET
Updated Mar 01, 2023 08:53AM ET
By Geoffrey Smith
Investing.com -- Eli Lilly (NYSE:LLY) said it will cut the price of its most commonly prescribed diabetes drugs by 70% and cap out-of-pocket costs for patients at $35 a month, bowing to pressure from the public and from politicians.
The price cuts will only be introduced in stages, and won't apply to its branded Humalog drug – the one most commonly prescribed for diabetes sufferers - until the fourth quarter.
Lilly will start by cutting the price of its non-branded insulin, Lispro Injection to $25 a vial from May 1st. Lilly, which has a 30% market share in the U.S. for insulin drugs, said this will make it the lowest list price mealtime insulin on the market.
As of October, it will cut the list price of Humalog and Humulin by 70%.
"While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone and that needs to change," said Lilly's chairman and CEO David Ricks.
He added that "Because these price cuts will take time for the insurance and pharmacy system to implement, we are taking the additional step to immediately cap out-of-pocket costs for patients who use Lilly insulin and are not covered by the recent Medicare Part D cap."
The new limit on out-of-pocket costs is in line with the cap outlined by U.S. President Joe Biden on Tuesday, who accused the pharma industry of profiteering with regard to a disease that affects 10% of Americans.
"Look at the profit margins of these companies," Biden said. "They're hundreds of billions of dollars. It's not — it's not like they're getting hurt."
Eli Lilly stock fell 0.3% in premarket trading in response. The shares have been under pressure from political campaigning against its pricing policies for several months already.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.